Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
FDA Approves 56 New AI Radiology Devices, Total Tops 1,000
FDA updates its list with 56 new AI-powered radiology devices, bringing the total to over 1,000 approved tools.
•Radiology Business
a2z Radiology Raises $5M, Lands FDA Clearance for Multi-Condition CT AI
Boston-based a2z Radiology raised $4.5M and earned FDA clearance for its Unified Triage AI solution for abdominal and pelvic CT scans.
•AuntMinnie
AI Ultrasound Tool May Cut Unnecessary Breast Biopsies by 60%
An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.